Treatment with a vascular disrupting agent does not increase recruitment of indium labelled human endothelial outgrowth cells in an experimental tumour model

BMC Cancer

Michael R Horsman¹  Hans Stødkilde-Jørgensen²  Lise Falborg⁴  Yuan Yuan Shen³  Anja B Bohn¹  Lotte B Bertelsen² 

[1]Department Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark

[2]MR-Research Centre, Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark

[3]The Affiliated Hospital of Binzhou Medical University, Binzhou, Shandong, China

[4]Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, Aarhus, Denmark

关键词: Tumour;    CA4P;    Vascular disrupting agents;    Endothelial outgrowth cells;   

Others  :  1117967
DOI  :  10.1186/1471-2407-14-903

 received in 2014-02-21, accepted in 2014-11-26,  发布年份 2014

【 摘 要 】

Background

The effect of vascular disrupting agents in tumour therapy depends on both the immediate vascular shutdown, and on the following re-vascularization of the tumour. The aim of this study was to use a tumour model to investigate whether endothelial outgrowth cells (EOCs) influenced the short term treatment efficiency of combretastatin A-4 disodium phosphate (CA4P) and 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by increasing EOC tumour recruitment.

Methods

In order to visualize the recruitment of EOCs to the tumours, umbilical cord blood derived human EOCs were labelled with ¹¹¹Indium-tropolone in a dose of 0.37 MBq pr 3×10⁶ cells and were injected intravenously into mice carrying a C3H mammary carcinoma on their right rear foot. DMXAA and CA4P in different concentrations and at different exposure times were used to create a hypoxic environment in the C3H mammary carcinoma in the mice. Three different mice strains with various degrees of functional immune system were used to study the homing capability of EOCs.

Results

Our data showed that approximately 4% of the total injected radioactive dose per gram of tissue was found in the tumour after treatment with CA4P and DMXAA. Regardless of the concentration and the treatment duration, CA4P did not increase EOC recruitment to the tumour in comparison to EOC recruitment in control tumours in any of the 3 mice strains studied.

Conclusion

Our data showed that regardless of the grade of the immune system, ranging from a fully working to a fully compromised immune system, treatment with CA4P did not increase recruitment of xenotransplanted EOCs to tumour tissue.

【 授权许可】

   
2014 Bertelsen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM: Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275:964-967.
• [2]Tura O, Skinner EM, Barclay GR, Samuel K, Gallagher RC, Brittan M, Hadoke PW, Newby DE, Turner ML, Mills NL: Late outgrowth endothelial cells resemble mature endothelial cells and are not derived from bone marrow. Stem Cells 2013, 31:338-348.
• [3]Nolan DJ, Ciarrocchi A, Mellick AS, Jaggi JS, Bambino K, Gupta S, Heikamp E, McDevitt MR, Scheinberg DA, Benezra R, Mittal V: Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev 2007, 21:1546-1558.
• [4]Khakoo AY, Finkel T: Endothelial progenitor cells. Annu Rev Med 2005, 56:79-101.
• [5]Ingram DA, Caplice NM, Yoder MC: Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells. Blood 2005, 106:1525-1531.
• [6]Timmermans F, Plum J, Yoder MC, Ingram DA, Vandekerckhove B, Case J: Endothelial progenitor cells: identity defined? J Cell Mol Med 2009, 13:87-102.
• [7]Urbich C, Dimmeler S: Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 2004, 95:343-353.
• [8]Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, Hicklin DJ, Chaplin D, Foster FS, Benezra R, Kerbel RS: Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006, 313:1785-1787.
• [9]Taylor M, Billiot F, Marty V, Rouffiac V, Cohen P, Tournay E, Opolon P, Louache F, Vassal G, Laplace-Builhe C, Vielh P, Soria JC, Farace F: Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells. Cancer Discov 2012, 2:434-449.
• [10]Ingram DA, Mead LE, Tanaka H, Meade V, Fenoglio A, Mortell K, Pollok K, Ferkowicz MJ, Gilley D, Yoder MC: Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 2004, 104:2752-2760.
• [11]Barclay GR, Tura O, Samuel K, Hadoke PW, Mills NL, Newby DE, Turner ML: Systematic assessment in an animal model of the angiogenic potential of different human cell sources for therapeutic revascularization. Stem Cell Res Ther 2012, 3:23. BioMed Central Full Text
• [12]Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, Krasich R, Temm CJ, Prchal JT, Ingram DA: Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007, 109:1801-1809.
• [13]Pagan J, Przybyla B, Jamshidi-Parsian A, Gupta K, Griffin RJ: Blood outgrowth endothelial cells increase tumor growth rates and modify tumor physiology: relevance for therapeutic targeting. Cancers (Basel) 2013, 5:205-217.
• [14]Aicher A, Brenner W, Zuhayra M, Badorff C, Massoudi S, Assmus B, Eckey T, Henze E, Zeiher AM, Dimmeler S: Assessment of the tissue distribution of transplanted human endothelial progenitor cells by radioactive labeling. Circulation 2003, 107:2134-2139.
• [15]Mitchell AJ, Sabondjian E, Sykes J, Deans L, Zhu W, Lu X, Feng Q, Prato FS, Wisenberg G: Comparison of initial cell retention and clearance kinetics after subendocardial or subepicardial injections of endothelial progenitor cells in a canine myocardial infarction model. J Nucl Med 2010, 51:413-417.
• [16]Vaupel P, Kallinowski F, Okunieff P: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989, 49:6449-6465.
• [17]Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
• [18]Kerbel R, Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002, 2:727-739.
• [19]Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR, Marme D, Lorusso PM: Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 2005, 11:416-420.
• [20]Horsman MR, Siemann DW: Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 2006, 66:11520-11539.
• [21]Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ: Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997, 57:1829-1834.
• [22]Murata R, Siemann DW, Overgaard J, Horsman MR: Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol 2001, 60:155-161.
• [23]Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, Dennis MF, Chaplin DJ: Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 1999, 59:1626-1634.
• [24]Murata R, Overgaard J, Horsman MR: Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. Int J Radiat Biol 2001, 77:195-204.
• [25]Tozer GM, Kanthou C, Baguley BC: Disrupting tumour blood vessels. Nat Rev Cancer 2005, 5:423-435.
• [26]Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia-Kendall D: Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 1989, 45:209-211.
• [27]Baguley BC: Antivascular therapy of cancer: DMXAA. Lancet Oncol 2003, 4:141-148.
• [28]Roberts ZJ, Ching LM, Vogel SN: IFN-beta-dependent inhibition of tumor growth by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). J Interferon Cytokine Res 2008, 28:133-139.
• [29]Greenberg DA, Jin K: From angiogenesis to neuropathology. Nature 2005, 438:954-959.
• [30]Hattori K, Dias S, Heissig B, Hackett NR, Lyden D, Tateno M, Hicklin DJ, Zhu Z, Witte L, Crystal RG, Moore MA, Rafii S: Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 2001, 193:1005-1014.
• [31]Rafii S, Heissig B, Hattori K: Efficient mobilization and recruitment of marrow-derived endothelial and hematopoietic stem cells by adenoviral vectors expressing angiogenic factors. Gene Ther 2002, 9:631-641.
• [32]Iwaguro H, Yamaguchi J, Kalka C, Murasawa S, Masuda H, Hayashi S, Silver M, Li T, Isner JM, Asahara T: Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation 2002, 105:732-738.
• [33]Overgaard J: Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo. Int J Radiat Oncol Biol Phys 1980, 6:1507-1517.
• [34]Timmermans F, Van HF, De SM, Raedt R, Plasschaert F, De Buyzere ML, Gillebert TC, Plum J, Vandekerckhove B: Endothelial outgrowth cells are not derived from CD133+ cells or CD45+ hematopoietic precursors. Arterioscler Thromb Vasc Biol 2007, 27:1572-1579.
• [35]Bertelsen LB, Hagensen M, Busk M, Zhang R, Knudsen AS, Nielsen N, Falborg L, Moller BK, Horsman MR, Stodkilde-Jorgensen H: In vivo bio-distribution and homing of endothelial outgrowth cells in a tumour model. Nucl Med Biol 2014, 41:848-855.
• [36]Murata R, Overgaard J, Horsman MR: Potentiation of the anti-tumour effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid. Int J Hyperthermia 2001, 17:508-519.
• [37]Iwami Y, Masuda H, Asahara T: Endothelial progenitor cells: past, state of the art, and future. J Cell Mol Med 2004, 8:488-497.
• [38]Bertolini F, Shaked Y, Mancuso P, Kerbel RS: The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 2006, 6:835-845.
• [39]Horsman MR, Ehrnrooth E, Ladekarl M, Overgaard J: The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int J Radiat Oncol Biol Phys 1998, 42:895-898.
• [40]Tozer GM, Kanthou C, Parkins CS, Hill SA: The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 2002, 83:21-38.
• [41]Nielsen T, Murata R, Maxwell RJ, Stodkilde-Jorgensen H, Ostergaard L, Horsman MR: Preclinical studies to predict efficacy of vascular changes induced by combretastatin a-4 disodium phosphate in patients. Int J Radiat Oncol Biol Phys 2008, 70:859-866.
• [42]Lingen MW: Role of leukocytes and endothelial cells in the development of angiogenesis in inflammation and wound healing. Arch Pathol Lab Med 2001, 125:67-71.
• [43]Dudek AZ, Bodempudi V, Welsh BW, Jasinski P, Griffin RJ, Milbauer L, Hebbel RP: Systemic inhibition of tumour angiogenesis by endothelial cell-based gene therapy. Br J Cancer 2007, 97:513-522.